J&J to join Poolbeg on key cancer drug trial

Trial will test Poolbeg’s drug which could prevent the severe side effects faced by patients receiving immunotherapy treatments

Jeremy Skillington, chief executive officer of Poolbeg Pharma. Johnson & Johnson is to join with Poolbeg Pharma on a key cancer drug trial in the UK.  

Johnson & Johnson is to join with Poolbeg Pharma on a key cancer drug trial in the UK.

Dublin-headquartered Poolbeg, co-founded by Cathal Friel, is taking part in an upcoming clinical trial which is being run out of The Christie in Manchester.